Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine

Multi-targeted immunotherapeutics to treat B cell malignancies - ScienceDirect

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells. - Abstract - Europe PMC

Frontiers Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy

IFN-γ independent markers of Mycobacterium tuberculosis exposure among male South African gold miners - eBioMedicine

Ida H Hiemstra's research works Genmab, Copenhagen and other places

Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models - ScienceDirect

Biomedicines, Free Full-Text

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. - Abstract - Europe PMC

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine

Full article: The Cancer-Immunity Cycle in Multiple Myeloma

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine

Frontiers Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy

PDF) Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine